173 related articles for article (PubMed ID: 29997148)
41. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
42. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
43. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
44. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Liu Y; Zhang X; Liu J; Hou G; Zhang S; Zhang J
Tumour Biol; 2014 Feb; 35(2):1275-86. PubMed ID: 24014089
[TBL] [Abstract][Full Text] [Related]
45. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
[TBL] [Abstract][Full Text] [Related]
46. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
47. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.
Aristizabal Prada ET; Orth M; Nölting S; Spöttl G; Maurer J; Auernhammer C
PLoS One; 2017; 12(5):e0178375. PubMed ID: 28542590
[TBL] [Abstract][Full Text] [Related]
48. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
49. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
50. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
51. Dual inhibition of mTORC1/2 by DCZ0358 induces cytotoxicity in multiple myeloma and overcomes the protective effect of the bone marrow microenvironment.
Gao L; Li B; Yang G; Liu P; Lan X; Chang S; Tao Y; Xu Z; Xie B; Sun X; Wang Y; Hu L; Yu D; Xie Y; Bu W; Wu X; Zhu W; Shi J
Cancer Lett; 2018 May; 421():135-144. PubMed ID: 29428642
[TBL] [Abstract][Full Text] [Related]
52. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Lin G; Lin KJ; Wang F; Chen TC; Yen TC; Yeh TS
Dis Model Mech; 2018 May; 11(8):. PubMed ID: 29666220
[TBL] [Abstract][Full Text] [Related]
53. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
54. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
55. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
57. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
58. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
59. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
[TBL] [Abstract][Full Text] [Related]
60. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Chen L; Yang G; Dong H
Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
